Previous 10 | Next 10 |
2024-05-31 07:00:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Morgan Stanley recently released its bullish take on the biotech space, driven by anticipated interest rate cuts and a surge in mergers and acquisitions (M&A) activity. The analyst firm...
2024-05-31 05:47:00 ET Once upon a time, Ginkgo Bioworks (NYSE: DNA) was viewed by many as a rising star in the biotechnology world. However, since its initial public offering in September 2021, the stock has plunged 95%. So far in 2024, Ginkgo's shares have fallen more than 60%. ...
2024-05-30 15:54:21 ET The Russell 3000 index will have a new look on June 28, after the market closes, when 225 securities will be added and 144 securities will be deleted as part of the annual reconstitution. Following are some notable healthcare companies which will be added and ...
2024-05-30 06:30:00 ET In the last three months, Ginkgo Bioworks ' (NYSE: DNA) shares fell by 50%. To the enterprising investor, such a decline by the Boston-based biotech specialist isn't necessarily a sign of disaster, and in fact could well be a sign of an opportunity to buy shar...
2024-05-29 20:54:18 ET Summary Ole Andreas Halvorsen's 13F stock portfolio value decreased from $27.3B to $26.9B in Q1 2024. The number of holdings in the portfolio increased from 79 to 83. The largest five individual stock positions are Visa, Workday, Amazon.com, Philip Morri...
2024-05-25 08:30:00 ET Thanks to its promises of low-cost bioengineering and biomanufacturing services, Ginkgo Bioworks (NYSE: DNA) could one day be the kind of biotech that everyone else in the biopharma sector wants to work with to advance their own products. Delivering on those p...
2024-05-25 04:57:00 ET It has been difficult to be a shareholder of Ginkgo Bioworks (NYSE: DNA) over the past year. The stock has collapsed about 72% from its peak last summer. The company's cell engineering foundry is an amazing accomplishment, but sales have stagnated. If this...
2024-05-20 12:40:00 ET Ginkgo Bioworks (NYSE: DNA) stock has dropped more than 10% since its latest quarterly report showing a more than 53% decline in Q1 revenue and continued net losses from its business. BTIG analyst Mark Massaro downgraded Ginkgo stock to sell, and lowered h...
2024-05-18 14:38:00 ET Ginkgo Bioworks (NYSE: DNA) is a cell programming company that claims to have large addressable markets (for bioengineered products) in multiple industries in which it can play a key role, and that those are worth trillions of dollars in total. But the pro...
2024-05-16 11:01:24 ET Billionaire Larry Robbins' Glenview Capital Management took a stake in Broadcom ( NASDAQ: AVGO ), exited its position in Intel ( NASDAQ: INTC ), and substantially added to holdings in health insurers in Q1 2024, among other changes.... Read the f...
News, Short Squeeze, Breakout and More Instantly...
Ginkgo Bioworks Holdings Inc. Class A Company Name:
DNA Stock Symbol:
NYSE Market:
Ginkgo Bioworks Holdings Inc. Class A Website:
A look at the top 10 most actives in the United States Yoshitsu Co. Ltd (TKLF) rose 103.4% to $0.623 on volume of 309,019,720 shares Maxeon Solar Technologies Ltd. (MAXN) rose 11.2% to $0.2524 on volume of 226,231,487 shares NVIDIA Corporation (NVDA) fell 1.6% to $126.36 on volume of 208,...
Syngenta collaborates with Ginkgo Bioworks to enable faster launch of innovative biologicals PR Newswire Syngenta will leverage Ginkgo's Ag Biologicals capabilities to optimize secondary metabolite production for a pioneering biological solution BASEL, Switzerland ...